Trial
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Pediatric Cancer (Oncology)
Medulloblastoma (High Risk)
This randomized phase III trial studies different chemotherapy and radiation therapy regimens to compare how well they work in treating young patients with newly diagnosed, previously untreated, high-risk medulloblastoma. Drugs used in chemotherapy, such as vincristine sulfate, cisplatin, cyclophosphamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Isotretinoin may help chemotherapy work better by making tumor cells more sensitive to the drugs. Radiation therapy uses high-energy x-rays to kill tumor cells. Carboplatin may make tumor cells more sensitive to radiation therapy. It is not yet known which chemotherapy and radiation therapy regimen is more effective in treating brain tumors.
All patients must begin therapy within 31 days of diagnostic surgery
Age: >3 and <22 years of age at the time of diagnosis
Enrollment onto ALTE07C1 is strongly encourage (neurocognitive testing study)
Newly diagnosed, previously untreated medulloblastoma including pineoblastoma
Diffusely anaplastic medulloblastoma are eligible
All patients with M4 disease are not eligible
No previous chemotherapy or radiation therapy
Patients taking Accutane (Isotretinoin) for acne must discontinue drug use with this indication prior to enrollment
Corticosteroids should not be used during chemotherapy as an antiemetic because of their effect on the blood-brain barrier
No other experimental therapy is permitted while on study
Adequate kidney, liver, and bone marrow function
Principal Investigator Name
Janice Olson, MD
Children's Cancer and Blood Disorders Program
Last Updated:
Wednesday, January 27, 2021 11:41:12 AM